Melphalan hydrochloride and Oesophagitis - a phase IV clinical study of FDA data


Oesophagitis is found among people who take Melphalan hydrochloride, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Melphalan hydrochloride and have Oesophagitis. It is created by eHealthMe based on reports of 3,830 people who have side effects when taking Melphalan hydrochloride from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On Jun, 25, 2022

3,830 people reported to have side effects when taking Melphalan hydrochloride.
Among them, 21 people (0.55%) have Oesophagitis.

What is Melphalan hydrochloride?

Melphalan hydrochloride has active ingredients of melphalan hydrochloride. eHealthMe is studying from 3,835 Melphalan hydrochloride users for its effectiveness, alternative drugs and more.

What is Oesophagitis?

Oesophagitis (inflammation of oesophagus) is found to be associated with 1,719 drugs and 982 conditions by eHealthMe.

Number of Melphalan hydrochloride and Oesophagitis reports submitted per year:

Could Melphalan hydrochloride cause Oesophagitis?

Gender of people who have Oesophagitis when taking Melphalan hydrochloride *:

  • female: 55.56 %
  • male: 44.44 %

Age of people who have Oesophagitis when taking Melphalan hydrochloride *:

  • 0-1: 0.0 %
  • 2-9: 25 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 25 %
  • 50-59: 0.0 %
  • 60+: 50 %

Common drugs people take besides Melphalan hydrochloride *:

  1. Neurontin: 15 people, 71.43%
  2. Zometa: 14 people, 66.67%
  3. Coumadin: 14 people, 66.67%
  4. Revlimid: 14 people, 66.67%
  5. Peridex: 13 people, 61.90%
  6. Simvastatin: 13 people, 61.90%
  7. Lyrica: 10 people, 47.62%
  8. Clonazepam: 9 people, 42.86%
  9. Cymbalta: 9 people, 42.86%
  10. Depo-Medrol: 9 people, 42.86%

Common side effects people have besides Oesophagitis *:

  1. Abdominal Pain: 14 people, 66.67%
  2. Chest Pain: 14 people, 66.67%
  3. Infection: 14 people, 66.67%
  4. Indigestion: 14 people, 66.67%
  5. Hypoaesthesia (reduced sense of touch or sensation): 14 people, 66.67%
  6. Neuropathy Peripheral (surface nerve damage): 14 people, 66.67%
  7. Osteonecrosis Of Jaw (death of bone of jaw): 14 people, 66.67%
  8. Pain: 14 people, 66.67%
  9. Pain In Jaw: 14 people, 66.67%
  10. Constipation: 14 people, 66.67%

Common conditions people have *:

  1. Multiple Myeloma (cancer of the plasma cells): 20 people, 95.24%
  2. Pain: 1 person, 4.76%
  3. Nausea And Vomiting: 1 person, 4.76%
  4. Nausea (feeling of having an urge to vomit): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Melphalan hydrochloride and have Oesophagitis?

Check whether Oesophagitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of Melphalan hydrochloride:

Oesophagitis treatments and more:

COVID vaccines that are related to Oesophagitis:

How severe was Oesophagitis and when was it recovered:

Expand to all the drugs that have ingredients of melphalan hydrochloride:

Common drugs associated with Oesophagitis:

All the drugs that are associated with Oesophagitis:

Common conditions associated with Oesophagitis:

All the conditions that are associated with Oesophagitis:

How the study uses the data?

The study uses data from the FDA. It is based on melphalan hydrochloride (the active ingredients of Melphalan hydrochloride) and Melphalan hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: